Literature DB >> 1663983

Influence of betaxolol on renal function and atrial natriuretic peptide in essential hypertension.

M Hollenbeck1, J Plum, P Heering, B Kutkuhn, B Grabensee.   

Abstract

The hypotensive action of beta-adrenoreceptor blockers is not fully understood, there being a lack of studies focusing on possible relationships between beta-blockers and the secretion of atrial natriuretic peptide (ANP). In 10 patients with essential hypertension, we investigated the influence of betaxolol, a selective beta 1-adrenergic blocking agent, on renal function and on plasma levels of ANP during exercise, volume depletion and volume expansion. Chronic therapy with betaxolol (mean 14.5 mg/day) did not alter glomerular filtration rate and renal blood flow although blood pressure was reduced. Renal vascular resistance decreased from 12795 +/- 1064 dyn/s per cm5 to 10614 +/- 833 dyn/s per cm5 (P less than 0.005). Under betaxolol, basal ANP levels increased from 39 +/- 10 pg/ml to 80 +/- 19pg/ml (P less than 0.01). ANP increased during exercise and volume expansion but was decreased during volume depletion. ANP values observed under betaxolol treatment showed significantly higher values while preserving their dynamic features. We believe that the stimulating effect of betaxolol on ANP may at least partly account for its hypotensive action.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1663983

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  3 in total

1.  Beta-adrenoceptor blockade potentiates acute exercise-induced release of atrial natriuretic peptide by increasing atrial diameter in normotensive healthy subjects.

Authors:  I Berlin; P Lechat; G Deray; C Landault; G Maistre; V Chermat; R Brouard; C Ressayre; A J Puech
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 2.  Atrial natriuretic peptide contributes to the antihypertensive action of many drugs.

Authors:  C L Papadopoulos; B A Kokkas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jan-Mar       Impact factor: 2.441

3.  Plasma atrial natriuretic peptide in essential hypertension after treatment with terazocin.

Authors:  P Kotridis; B Kokkas; P Kyriakou; M Karamouzis; G Salpigidis; C Karantona; J Karadoumanis; T Ginis; O Goulis; P C Papadopoulos; C Vakalopoulos; G Sakantamis; A Dimitriadou; V Mirtsou-Fidani; C L Papadopoulos
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Apr-Jun       Impact factor: 2.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.